In May 2002, a meeting was held in Montreal, Canada, with the purpose of (1) arriving at a consensus on whether omega-3 LC-PUFA supplementation would reduce the risk of CHD death in a high-risk, primary prevention population, and (2) whether a primary prevention trial was needed and feasible to undertake. In the eventuality that the answers to both questions were affirmative, a second objective would be to focus on the essential elements of a protocol that would be scientifically valid, medically relevant, practical and fundable. Participants concluded that a high-risk, primary prevention trial was highly desirable in light of the rapidly growing evidence for cardioprotection in the secondary prevention setting and was feasible.
|Original language||English (US)|
|Number of pages||2|
|Specialist publication||INFORM - International News on Fats, Oils and Related Materials|
|State||Published - Aug 2004|
ASJC Scopus subject areas
- Food Science